Back to Search
Start Over
Microbiome composition recovery after liver transplantation correlates with initial liver disease severity and antibiotics treatment.
- Source :
-
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2024 Sep; Vol. 24 (9), pp. 1623-1633. Date of Electronic Publication: 2024 Mar 29. - Publication Year :
- 2024
-
Abstract
- Liver transplantation (LT) is crucial for end-stage liver disease, but it is linked to infection risks. Pathobionts, microorganisms potentially harmful under specific conditions, can cause complications posttransplant. Monitoring such pathogens in fecal samples can be challenging and therefore remains underexplored post-LT. This study aimed to analyze the gut microbiome before and after LT, tracking pathobionts and correlating clinical data. The study involved 17 liver transplant recipients, 17 healthy relatives (spouses), and 13 donors. Gut samples collected pretranplantation and posttransplantation underwent bacterial and fungal profiling through DNA sequencing. Quantitative polymerase chain reaction was used to assess microbial load. Statistical analyses included alpha and beta diversity measures, differential abundance analysis, and correlation tests between microbiome and clinical parameters. Microbiome analysis revealed dynamic changes in diversity posttransplant. Notably, high-severity patients showed persistent and greater dysbiosis during the first months post-LT compared with low-severity patients, partly due to an antibiotic treatment pre-LT. The analysis identified a higher proportion of pathogens such as Escherichia coli/Shigella flexneri in high-severity cases posttransplant. Furthermore, butyrate producers including Roseburia intestinalis, Anaerostipes hadrus, and Eubacterium coprostanoligenes were positively correlated with levels of albumin. This study offers valuable insights into post-LT microbiome changes, shedding light on the need for tailored prophylactic treatment post-LT.<br />Competing Interests: Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation: TEVA Pharmaceutical has partially funded the study.<br /> (Copyright © 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Male
Female
Middle Aged
Follow-Up Studies
Prognosis
Adult
Feces microbiology
Dysbiosis microbiology
Dysbiosis etiology
Severity of Illness Index
Bacteria isolation & purification
Bacteria genetics
Bacteria classification
Postoperative Complications microbiology
Case-Control Studies
Graft Survival
Aged
Tissue Donors
Liver Transplantation adverse effects
Gastrointestinal Microbiome drug effects
Anti-Bacterial Agents therapeutic use
End Stage Liver Disease surgery
Subjects
Details
- Language :
- English
- ISSN :
- 1600-6143
- Volume :
- 24
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Publication Type :
- Academic Journal
- Accession number :
- 38556088
- Full Text :
- https://doi.org/10.1016/j.ajt.2024.03.038